EGFR and adenocarcinoma: In adenocarcinoma patients, EGFR–TKI objective response rates, OS, and PFS are 66–74%, 19–21 months, and 9.4–10 months (9) versus 25–27%, 13.48 months, and 3–5 months for SQCC (10, 11), respectively.